Source: Pharmacy compounding company valued at $900 million.
FORTUNE -- Private equity firm Clayton Dubilier & Rice today said that it has completed its previously-announced acquisition of a majority stake in PharMEDium from Oak Investment Partners and Baird Capital.
No financial terms were disclosed, but Fortune has learned that the deal was done at around a $900 million enterprise valuation.
For Oak this represents around a 6x return on its 2007 investment, when MORE